Revive Extends Bucillamine Patent Shield Across Nerve-Agent and Infectious Disease Uses

Revive Therapeutics ( (TSE:RVV) ) has issued an announcement.

Revive Therapeutics has expanded its intellectual property portfolio around bucillamine by filing U.S. and Canadian patent applications covering the use of the drug to treat victims exposed to chemical warfare nerve agents, while also securing a Canadian patent for its use in treating or preventing infectious diseases such as influenza and COVID-19. The company says these moves deepen long-term exclusivity for one of its key pipeline assets and position bucillamine as a versatile platform across infectious disease, public-health emergencies and government-funded medical countermeasures, supporting potential opportunities in biodefense stockpiling, future partnerships and broader applications including organophosphate poisoning and traumatic brain injury.

The most recent analyst rating on (TSE:RVV) stock is a Hold with a C$0.02 price target. To see the full list of analyst forecasts on Revive Therapeutics stock, see the TSE:RVV Stock Forecast page.

Spark’s Take on TSE:RVV Stock

According to Spark, TipRanks’ AI Analyst, TSE:RVV is a Neutral.

The score is primarily constrained by weak financial performance: no revenue, ongoing losses and cash burn, and a significantly weakened balance sheet with negative equity and sharply reduced assets. Technicals are mixed (some short-term support above key moving averages but still below the 200-day trend), and valuation is limited by negative earnings and no dividend.

To see Spark’s full report on TSE:RVV stock, click here.

More about Revive Therapeutics

Revive Therapeutics Ltd. is a life sciences company focused on developing treatments for infectious diseases and medical countermeasures, including therapies for chemical and biological threats. Its lead asset is bucillamine, a thiol-based drug with a long clinical history in rheumatoid arthritis and emerging applications in viral infections and nerve-agent exposure.

Average Trading Volume: 309,697

Technical Sentiment Signal: Hold

Current Market Cap: C$8.37M

Find detailed analytics on RVV stock on TipRanks’ Stock Analysis page.